Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

被引：0

作者：

Relinde I. Y. Lieverse

Evert J. Van Limbergen

Cary J. G. Oberije

Esther G. C. Troost

Sine R. Hadrup

Anne-Marie C. Dingemans

Lizza E. L. Hendriks

Franziska Eckert

Crispin Hiley

Christophe Dooms

Yolande Lievens

Monique C. de Jong

Johan Bussink

Xavier Geets

Vincenzo Valentini

Giuliano Elia

Dario Neri

Charlotte Billiet

Amir Abdollahi

David Pasquier

Pierre Boisselier

Ala Yaromina

Dirk De Ruysscher

Ludwig J. Dubois

Philippe Lambin

机构：

[1] Maastricht University,The D

[2] Maastricht University Medical Center,Lab and The M

[3] Faculty of Medicine and University Hospital Carl Gustav Carus at Technische Universität Dresden,Lab, Department of Precision Medicine, GROW

[4] OncoRay, School for Oncology and Developmental Biology

[5] National Center for Radiation Research in Oncology,Department of Radiation Oncology (MAASTRO), GROW

[6] Technical University of Denmark, School for Oncology and Developmental Biology

[7] Erasmus MC Rotterdam,Department of Radiotherapy and Radiation Oncology

[8] Maastricht University Medical Centre,Department of Health Technology

[9] University Hospital and Medical Faculty Tübingen,Department of Pulmonary Medicine

[10] Eberhard Karls University Tübingen,Department of Pulmonary Diseases, GROW

[11] University College London Cancer Institute, School for Oncology and Developmental Biology

[12] University Hospitals KU Leuven,Department of Radiation Oncology

[13] Ghent University Hospital and Ghent University,Cancer Research UK Lung Cancer Centre of Excellence

[14] Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital,Department of Respiratory Diseases, Respiratory Oncology Unit

[15] Radboud University Medical Center,Department of Radiation Oncology

[16] Cliniques Universitaires Saint-Luc,Department of Radiation Oncology

[17] MIRO - IREC Lab,Department of Radiation Oncology

[18] UCL,Department of Radiation Oncology

[19] Fondazione Policlinico Universitario A. Gemelli IRCCS,Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia

[20] Università Cattolica del Sacro Cuore,Department of Chemistry and Applied Biosciences

[21] Istituto di Radiologia,Department of Radiation Oncology

[22] Philochem AG,University of Antwerp

[23] Institute of Pharmaceutical Sciences,Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology

[24] ETH Zurich,Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT)

[25] Iridium Network,Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO)

[26] Faculty of Medicine and Health Sciences,Academic Department of Radiation Oncology

[27] Campus Drie Eiken,Department of Radiation Oncology, ICM

[28] Building S,Val d’Aurelle

[29] Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD),undefined

[30] Heidelberg Ion-Beam Therapy Center (HIT),undefined

[31] Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ),undefined

[32] German Cancer Consortium (DKTK) Core Center,undefined

[33] Heidelberg University and German Cancer Research Center (DKFZ),undefined

[34] Oscar Lambret Comprehensive Cancer Center,undefined

[35] Université de Montpellier,undefined

来源：

BMC Cancer | / 20卷

关键词：

Immunotherapy; L19-IL2; Anti-PD-L1; Anti-PD-1; Radiotherapy; SABR; Phase 2; NSCLC; Stage IV; Multicentre;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Gronberg, Bjorn Henning
Killingberg, Kristin Toftaker
Flotten, Oystein
Brustugun, Odd Terje
Hornslien, Kjersti
Madebo, Tesfaye
Langer, Seppo Wang
Schytte, Tine
Nyman, Jan
Risum, Signe
Tsakonas, Georgios
Engleson, Jens
Halvorsen, Tarje Onsoien
LANCET ONCOLOGY, 2021, 22 (03): : 321 - 331
[32] Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care
Gay, Marie Claire
Cassedanne, Fanny
Barbot, Frederic
Vaugier, Isabelle
Thomas, Sarah
Manchon, Eric
Bensmail, Djamel
Blanchere, Marie
Heinzlef, Olivier
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (02): : 158 - 166
[33] Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
Ou, Wei
Li, Ning
Wang, Bao-Xiao
Zhu, Teng-Fei
Shen, Zhi-Lin
Wang, Tao
Chang, Wu-Guang
Chang, Zeng-Hao
Hu, Xin-Xin
Pu, Yue
Ding, Lie -Ming
Wang, Si-Yu
ECLINICALMEDICINE, 2023, 57
[34] Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
Seco, Maria Pilar Ruiz
Pardo, Jose Ramon Pano
Schoergenhofer, Christian
Dings, Christiane
Lehr, Thorsten
Herth, Felix
Krendyukov, Andriy
Straub, Carola
Kappler, Martin
Jilma, Bernd
Fricke, Harald
Pardo, Julian
de Miguel, Diego
Thiemann, Meinolf
Bergmann, Michael
Walczak, Henning
Hoeger, Thomas
ECLINICALMEDICINE, 2024, 77
[35] Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial
Marsden, John
Kelleher, Mike
Gilvarry, Eilish
Mitcheson, Luke
Bisla, Jatinder
Cape, Angela
Cowden, Fiona
Day, Edward
Dewhurst, Jonathan
Evans, Rachel
Hardy, Will
Hearn, Andrea
Kelly, Joanna
Lowry, Natalie
McCusker, Martin
Murphy, Caroline
Murray, Robert
Myton, Tracey
Quarshie, Sophie
Vanderwaal, Rob
Wareham, April
Hughes, Dyfrig
Hoare, Zoe
ECLINICALMEDICINE, 2023, 66
[36] Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial (vol 402, pg 871, 2023)
Khabir, Yumna
LANCET, 2023, 402 (10405): : 850 - 850
[37] Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
Garin, Etienne
Tselikas, Lambros
Guiu, Boris
Chalaye, Julia
Edeline, Julien
de Baere, Thierry
Assenat, Eric
Tacher, Vania
Robert, Corentin
Terroir-Cassou-Mounat, Marie
Mariano-Goulart, Denis
Amaddeo, Giuliana
Palard, Xavier
Hollebecque, Antoine
Kafrouni, Marilyne
Regnault, Helene
Boudjema, Karim
Grimaldi, Serena
Fourcade, Marjolaine
Kobeiter, Hicham
Vibert, Eric
Le Sourd, Samuel
Piron, Lauranne
Sommacale, Daniele
Laffont, Sophie
Campillo-Gimenez, Boris
Rolland, Yan
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (01): : 17 - 29
[38] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Tree, Alison C.
Ostler, Peter
van der Voet, Hans
Chu, William
Loblaw, Andrew
Ford, Daniel
Tolan, Shaun
Jain, Suneil
Martin, Alexander
Staffurth, John
Armstrong, John
Camilleri, Philip
Kancherla, Kiran
Frew, John
Chan, Andrew
Dayes, Ian S.
Duffton, Aileen
Brand, Douglas H.
Henderson, Daniel
Morrison, Kirsty
Brown, Stephanie
Pugh, Julia
Burnett, Stephanie
Mahmud, Muneeb
Hinder, Victoria
Naismith, Olivia
Hall, Emma
van As, Nicholas
LANCET ONCOLOGY, 2022, 23 (10): : 1308 - 1320
[39] Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results
Reckamp, K. L.
Gilman, P.
Halmos, B.
Jahanzeb, M.
McCann, J.
Paripati, H.
Seneviratne, L. C.
Wallace, J. A.
Rueter, B.
Esler, A.
Dowling, E.
Koczywas, M.
ANNALS OF ONCOLOGY, 2018, 29 : 527 - 527
[40] Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapyto Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Tsai, Chiaojung Jillian
Yang, Jonathan
Shaverdian, Narek
Patel, Juber
Shepherd, Annemarie F.
Eng, Juliana
Guttmann, David
Yeh, Randy
Gelblum, Daphna Y.
Namakydoust, Azadeh
Preeshagul, Isabel
Modi, Shanu
Seidman, Andrew
Traina, Tiffany
Drullinsky, Pamela
Flynn, Jessica
Zhang, Zhigang
Rimner, Andreas
Gillespie, Erin F.
Gomez, Daniel R.
Lee, Nancy Y.
Berger, Michael
Robson, Mark E.
Reis-Filho, Jorge S.
Riaz, Nadeem
Rudin, Charles M.
Powell, Simon N.
LANCET, 2024, 403 (10422): : 171 - 182

← 1 2 3 4 5 →